Get the latest news, insights, and market updates on CVKD (Cadrenal Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why the underdog mindset could be your business superpower
You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this episode of Warrior Money, Patrick Murphy and Dan Kunze sit down with Cadrenal Therapeutics (CVKD) CEO Quang X. Pham to unpack the underdog mindset behind his journey from Vietnam to flying combat missions, leading in the pharmaceutical and biotech industries, and launching startups. Pham shares hard-earned lessons on choosing your first post-military job, focusing on where you want to live, and turning military skills into real-world leadership, sales, and small business success. They also delve into entrepreneurship through acquisition, utilizing tools such as SBA loans, and explain why veterans are uniquely positioned to take over baby boomer-owned businesses and build lasting wealth after their service. Hosted by former Congressman Patrick Murphy and veteran investor Dan Kunze, Yahoo Finance’s Warrior Money is a weekly podcast dedicated to uplifting military veterans transitioning into civilian life. Through insights from fellow veterans and high-ranking officials, Murphy and Kunze are helping set vets up for success through financial education and inspiration. This post was written by Langston Sessoms. Nov 17, 2025 - $CVKD
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi Nov 10, 2025 - $CVKD
CVKD: Acquires Factor XIa Inhibitors…
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires Portfolio of Factor XIa Inhibitors On September 15, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced it had acquired a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals. Included in the acquired assets is frunexian, a Phase 2-ready asset that is being developed as an acute Sep 30, 2025 - $CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p Sep 29, 2025 - $CVKD
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settingsCompany is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of Sep 15, 2025 - $CVKD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple